Oncology

Clinical Study

Phase II Study of an ‘All-Oral’ Regimen of Capecitabine, Idarubicin and Cyclophosphamide for Metastatic Breast Cancer – Safety, Efficacy and Quality of Life

Tong D.K.H. · Cheng C.W.N. · Ching Chan S.C. · Ngor Wong L.N. · Chow L.W.C.

Author affiliations

Hung Chao Hong Integrated Centre for Breast Diseases University of Hong Kong Medical Centre, Tung Wah Hospital, Hong Kong

Keywords: Breast carcinomaCapecitabineCyclophosphamideIdarubicinMetastatic breast cancerOral fluoropyrimidineQuality of life

Related Articles for ""
Oncology 2005;68:520–525
https://doi.org/10.1159/000086996

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: March 08, 2004
Accepted: November 14, 2004
Published online: August 17, 2005
Issue release date: August 2005

Number of Print Pages: 6
Number of Figures: 5
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Objective: Patients with metastatic breast cancer (MBC) generally have a poor prognosis. Many of these patients have a good performance status. A new all-oral regimen (XIC) was evaluated in a phase II trial. The impact of the regimen on the safety and efficacy of the drug, as well as quality of life (QOL) of the patients was assessed. Patients andMethods:From September 2000 to September 2001, informed consent was obtained from 20 heavily pretreated women with MBC. They were placed on a 6-week cycle regimen comprising capecitabine (X; 2,000 mg/m2/day in two divided doses for 2 weeks then 1 week rest), idarubicin (I; 10 mg/m2/day, days 1, 3 and 5) and cyclophosphamide (C; 100 mg/m2/day for 2 weeks then 1 week rest). Results: Toxicities were generally tolerable. One patient had grade III neutropenia, which was reversible on cessation of treatment. One patient (5%) had a complete response and 4 patients (20%) achieved partial responses, yielding an overall response rate of 25%. Eight patients (40%) had stable disease. Median time to disease progression and median survival time were 13.4 and 23.7 months, respectively. Global and physical EORTC QLQ-30 scores showed no significant decrease in QOL. Conclusion: This is a small-scale study. XIC was generally well tolerated and favoured by the patients. This moderately active and convenient ‘all-oral’ regimen deserves clinical trials at a wider scale.

© 2005 S. Karger AG, Basel



Related Articles:

References

  1. Gairard B, Mathelin C, Schaffer P, Brettes JP: Breast cancer: Epidemiology, risk factors, screening (in French). Rev Prat1998;48:21–27.
    External Resources
  2. Berry DA, Broadwater G, Klein JP, et al: High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002;20:743–750.
    External Resources
  3. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110–115.
    External Resources
  4. Borner MM, Schoffski P, de Wit R, et al: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349–358.
    External Resources
  5. Payne SA: A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992;35:1505–1509.
    External Resources
  6. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485–493.
    External Resources
  7. Wilke H: Future treatment options with capecitabine in solid tumours. Eur J Cancer 2002;38(suppl 2):21–25.
    External Resources
  8. Toffoli G, Sorio R, Aita P, et al: Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin Cancer Res2000;6:2279–2287.
    External Resources
  9. Aaronson NK, Ahmedzai S, Bergman B, et al:The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
    External Resources
  10. Wagstaff AJ, Ibbotson T, Goa KL: Capecitabine: A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs2003;63:217–236.
    External Resources
  11. Kerpel-Fronius S, Heinisch H: Oral idarubicin in treatment of advanced breast carcinoma (in German). Zentralbl Gynäkol 1996;118:587–589.
  12. Stewart DJ, Morgan LR Jr, Verma S, Maroun JA, Thibault M: Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study. Invest New Drugs 1995;13:99–107.
    External Resources
  13. Leonard RC, Cameron DA, Anderson A, Ostrowski J, Howell A: Idarubicin and cyclophosphamide – An active oral chemotherapy regimen for advanced breast cancer. Crit Rev Oncol Haematol 2000;33:61–66.
    External Resources
  14. Ackland SP, Anton A, Breitbach GP, et al:Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study. J Clin Oncol 2001;19:943–953.
    External Resources
  15. Fumoleau P, Largillier R, Trillet-Lenoir V, et al: Phase II study of capecitabine in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes. Breast Cancer Res Treat 2001;69:285.
    External Resources
  16. Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma. Cancer 2001;92:1759–1768.
    External Resources
  17. Reichardt P, von Minckwitz G, Luck HJ, et al: Capecitabine: The new standard in metastatic breast cancer failing anthracycline- and taxane-containing chemotherapy? Mature results of a large, multicenter phase II trial. Eur J Cancer2001;37(suppl 6):191.
    External Resources
  18. Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer2002;38:349–358.
    External Resources
  19. Heidemann E, Stoeger H, Souchon R, et al: Balance of time to progression, quality of life, and overall survival: More gain from treatment in single agent treatment with mitoxantrone (N) than with the combination of fluorouracil, epirubicin, cyclophosphamide (FEC). Results of a multicenter randomized trial in high-risk metastatic breast cancer (MBC). Proc Am Soc Clin Oncol2000;19:74a.
  20. Nightingale CE, Norman A, Cunningham D, Young J, Webb A, Filshie J: A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Eur J Cancer 1997;33:398–403.
    External Resources
  21. Poorter RL, Lauw FN, Bemelman WA, Bakker PJ, Taat CW, Veenhof CH: Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion chemotherapy. Eur J Cancer 1996;32:2262–2266.
    External Resources
  22. Sabel MS, Smith JL: Principles of chronic venous access: Recommendations based on the Roswell Park experience. Surg Oncol 1998;6:171–177.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: March 08, 2004
Accepted: November 14, 2004
Published online: August 17, 2005
Issue release date: August 2005

Number of Print Pages: 6
Number of Figures: 5
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2005, Vol.68, No. 4-6

August 2005

Article

Recommend This
TOP